Prof. Dr. Andreas Mackensen

Lehrstuhl für Innere Medizin V

Innovative cellular therapies for autoimmune diseases: expert-based position statement and clinical practice recommendations from the EBMT practice harmonization and guidelines committee. (2024) Greco R, Alexander T, Del Papa N, Müller F, Saccardi R, Sanchez-Guijo F, Schett G, et al. Journal article, Review article Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies (2024) Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kleyer A, Gary R, et al. Journal article, Letter Comment on: Rescue therapy of anti-synthetase syndrome with CD19-targeted CART cells after failure of several B cell-depleting antibodies: reply. (2024) Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kretschmann S, Atzinger A, et al. Journal article Successful generation of fully human, second generation, anti-CD19 CAR T cells for clinical use in patients with diverse autoimmune disorders (2024) Mougiakakos D, Sengupta R, Gold R, Schroers R, Haghikia A, Lorente M, Pendleton M, et al. Journal article Blockade of the CD47/SIRPα checkpoint axis potentiates the macrophage-mediated antitumor efficacy of tafasitamab. (2024) Biedermann A, Patra-Kneuer M, Mougiakakos D, Büttner-Herold M, Mangelberger-Eberl D, Berges J, Kellner C, et al. Journal article CD19-targeting CAR T-cell therapy in patients with diffuse systemic sclerosis: a case series (2024) Auth J, Müller F, Völkl S, Bayerl N, Distler JH, Tur C, Raimondo MG, et al. Journal article Determinants Affecting the Clinical Implementation of a Molecularly Informed Molecular Tumor Board Recommendation: Experience from a Tertiary Cancer Center. (2023) Tögel L, Schubart C, Lettmaier S, Neufert C, Hoyer J, Wolff K, Moskalev E, et al. Journal article Cytokine and reactivity profiles in SLE patients following anti-CD19 CART therapy (2023) Nunez D, Patel D, Volkov J, Wong S, Vorndran Z, Müller F, Aigner M, et al. Journal article Identification and characterization of T-cell receptors with therapeutic potential showing conserved specificity against all SARS-CoV 2 strains (2023) Reimann H, Moosmann C, Schober K, Lang V, Verhagen J, Zeun J, Mackensen A, et al. Journal article Inferior Outcomes of EU Versus US Patients Treated with CD19 CAR-T for Relapsed/Refractory Large B-cell Lymphoma: Association with Differences in Tumor Burden, Systemic Inflammation, Bridging Therapy Utilization, and CAR-T Product Use (2023) Bücklein V, Perez A, Rejeski K, Iacoboni G, Jurinovic V, Holtick U, Penack O, et al. Journal article